U.S. FDA Removes 27 Ranbaxy Generic Applications As Part Of Decree
This article was originally published in PharmAsia News
The U.S. FDA removed 27 Ranbaxy Laboratories applications for since-withdrawn generics as prescribed by a consent decree with the company earlier this year.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.